US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Eikon Therapeutics / Equity Capital Markets

<ul>
<li>Eikon Therapeutics (EIKN US) filed for its IPO on January 9, targeting a late-January or early-February market debut.</li>
<li>Lead candidate EIK1001, a TLR7/8 dual-agonist, is in global Phase 2/3 trials with pembrolizumab for advanced melanoma and Phase 2 NSCLC studies.</li>
<li>Eikon has raised over $1.1 billion across multiple rounds and collaborates with Seven and Eight Biotherapeutics and Cleave Therapeutics to expand its oncology pipeline.</li>
</ul>


Eikon Therapeutics (EIKN US) filed for its IPO on January 9, targeting a late-January or early-February market debut.
Lead candidate EIK1001, a TLR7/8 dual-agonist, is in global Phase 2/3 trials with pembrolizumab for advanced melanoma and Phase 2 NSCLC studies.
Eikon has raised over $1.1 billion across multiple rounds and collaborates with Seven and Eight Biotherapeutics and Cleave Therapeutics to expand its oncology pipeline.


Eikon Therapeutics (EIKN): Peeking at the IPO Prospectus of Targeting Advanced Melanoma

Global Healthcare Analyst

Tina Banerjee

IMPACT Therapeutics / Equity Capital Markets

<ul>
<li>Impact Therapeutics, a commercial-stage biotechnology company, has launched its HK IPO consisting of 42M H shares. The offer price is HK$21.75/share and shares will be sold in multiples of 200.</li>
<li>The company intends to raise $117M mainly to fund its R&amp;D.  The subscription period will close on May 8, with the shares expected to make trading debut on May 13.</li>
<li>The company’s self-developed core product, senaparib has been commercialized in China in January 2025 as a first-line maintenance therapy for ovarian cancer across all patient populations regardless of mutation status.</li>
</ul>


Impact Therapeutics, a commercial-stage biotechnology company, has launched its HK IPO consisting of 42M H shares. The offer price is HK$21.75/share and shares will be sold in multiples of 200.
The company intends to raise $117M mainly to fund its R&amp;D.  The subscription period will close on May 8, with the shares expected to make trading debut on May 13.
The company’s self-developed core product, senaparib has been commercialized in China in January 2025 as a first-line maintenance therapy for ovarian cancer across all patient populations regardless of mutation status.


Impact Therapeutics IPO: Clinically Compelling Core Product Lays Solid Foundation for Growth

AgomAb Therapeutics / Equity Capital Markets

<ul>
<li>AgomAb Therapeutics priced at $16.00 but opened down 8.1%, reflecting weak aftermarket support despite reported oversubscription.</li>
<li>Shares traded volatile on day one, hitting $12.66 before rebounding to close at $14.65, still below the IPO price.</li>
<li>The deal highlights the fragility of biotech IPO demand, where a few institutional orders can materially sway outcomes.</li>
</ul>


AgomAb Therapeutics priced at $16.00 but opened down 8.1%, reflecting weak aftermarket support despite reported oversubscription.
Shares traded volatile on day one, hitting $12.66 before rebounding to close at $14.65, still below the IPO price.
The deal highlights the fragility of biotech IPO demand, where a few institutional orders can materially sway outcomes.


AgomAb Therapeutics NV (AGMB): Biotech Selectivity on Display as AgomAb Trades Below IPO Price

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Forgent Power Solutions / Equity Capital Markets

<ul><li>Forgent Power Solutions (FPS) Forgent Power Solutions delivered the most constructive tape of the session, trading as a controlled trend day higher.</li><li>After opening near $26.00, FPS stair-stepped higher throughout the day, printing higher highs with shallow, orderly pullbacks.</li><li>The stock reached an intraday high near $29.70 before consolidating and ultimately closing near $29.34, firmly in the upper portion of the day’s range.</li></ul>

Forgent Power Solutions (FPS) Forgent Power Solutions delivered the most constructive tape of the session, trading as a controlled trend day higher.After opening near $26.00, FPS stair-stepped higher throughout the day, printing higher highs with shallow, orderly pullbacks.The stock reached an intraday high near $29.70 before consolidating and ultimately closing near $29.34, firmly in the upper portion of the day’s range.

End-of-Day IPO Review: Structure Without Confirmation - February 5, 2026

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Eikon Therapeutics (EIKN US)

Eikon Therapeutics (EIKN): Peeking at the IPO Prospectus of Targeting Advanced Melanoma

Eikon Therapeutics files for IPO, targeting market debut in late-January or early-February with lead candidate in global Phase 2/3 trials for...

IPO Boutique

Impact Therapeutics IPO: Clinically Compelling Core Product Lays Solid Foundation for Growth

Impact Therapeutics seeks to raise $117M via HK IPO consisting of 42M H shares at the offer price of HK$21.75/share mainly to fund its R&D. The...

Tina Banerjee

AgomAb Therapeutics NV (AGMB): Biotech Selectivity on Display as AgomAb Trades Below IPO Price

AgomAb Therapeutics IPO opens below price at $14.65, showing vulnerability of biotech IPO demand to institutional orders.

IPO Boutique

End-of-Day IPO Review: Structure Without Confirmation - February 5, 2026

Forgent Power Solutions (FPS) Forgent Power Solutions delivered the most constructive tape of the session, trading as a controlled trend day...

IPO Prophet

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Eikon Therapeutics (EIKN): Peeking at the IPO Prospectus of Targeting Advanced Melanoma

​Eikon Therapeutics files for IPO, targeting market debut in late-January or early-February with lead candidate in global Phase 2/3 trials for...

IPO Boutique

Impact Therapeutics IPO: Clinically Compelling Core Product Lays Solid Foundation for Growth

Impact Therapeutics seeks to raise $117M via HK IPO consisting of 42M H shares at the offer price of HK$21.75/share mainly to fund its R&D. The...

Tina Banerjee

AgomAb Therapeutics NV (AGMB): Biotech Selectivity on Display as AgomAb Trades Below IPO Price

​AgomAb Therapeutics IPO opens below price at $14.65, showing vulnerability of biotech IPO demand to institutional orders.

IPO Boutique

End-of-Day IPO Review: Structure Without Confirmation - February 5, 2026

Forgent Power Solutions (FPS) Forgent Power Solutions delivered the most constructive tape of the session, trading as a controlled trend day...

IPO Prophet

Eikon Therapeutics files for IPO, targeting market debut in late-January or early-February with lead candidate in global Phase 2/3 trials for...

AgomAb Therapeutics IPO opens below price at $14.65, showing vulnerability of biotech IPO demand to institutional orders.